Inovio Pharmaceuticals results miss on the bottom line; shares down 9%

CharlieAJA/iStock via Getty Images

• Inovio Pharmaceuticals' (NASDAQ:INO) Q4 2021 results missed on the bottom line as its net loss significantly widened.
• Shares are down 9% in after-market trading.
• Net loss in the quarter was $106.9M, ~340% increase from the prior-year period. Basic and diluted EPS in the quarter was -$0.50, compared to -$0.14 in the Q4 2020.
• Revenue of $839K in Q4 2021 was an 85% drop from the prior-year period.
• R&D expenses in the quarter shot up ~251% to $92.3M. Inovio (INO) said the increase was due to higher drug manufacturing expenses and clinical trials related to INO-4800.
• The company ended the year with $401.3M in cash.
• Read why Seeking Alpha contributor William Meyers considers Inovio (INO) a buy.

Comments

[Randol33]

Inovio’s research and development expenses for the quarter and year ended December 31, 2021 were $92.3 million and $249.2 million, compared to $26.3 million and $94.2 million for the same periods in 2020.

So they are burning thru cash at x3 times the rate of last year to hopefully produce a vaccine. Seems like they would be better off stopping all Covid actions and preserve capital for the next pandemic.

[break-point]

@Randol33 absolutely

[break-point]

Covid vaccine is just a waste of money!! They should stop ASAP.

[Fender5]

I guess the world will have to wait.

[break-point]

@Fender5 for what?

[Fender5]

@break-point exactly. It’s on the front page of Inovio’s website.

[break-point]

@Fender5 I have seen now....

[tkarl]

Buried in the press release: they paused enrollments in their Covid P3 trial.

[stephen tips]

"Seeking Alpha Contributor William Meyers considers Inovio (INO) a buy."

I believe that Mr. Meyers is spot on with his recommendation. He, as I, agree that VGX-3100 (now in the later stages of P3), should be the first FDA-approved commercial product for Inovio.

Inovio's covid-19 vaccine, INO-4800, could be a bonus for $INO, all recipients, shareholders and directors alike.

Quarterly earnings reports are not an indicator of future potential for clinical stage biotechnology companies that lack any commercial product. The year end $401.3M in cash is much more telling.

[Tambo210]

I remember trading weekly calls, this time last year.
Easy money.

Then parked the money elsewhere.

HPV vaccine work is the only reason to keep this stock and can save it.

[Randol33]

LOL. try down -75% from $31.25 it just happens to be down -10% after hours.